These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 16161529)
1. Enzymatic prostatic acid phosphatase in the clinical staging of patients diagnosed with prostate cancer. Merrick GS; Butler WM; Wallner KE; Allen Z; DeFilippo JL; Adamovich E W V Med J; 2005; 101(3):116-9. PubMed ID: 16161529 [TBL] [Abstract][Full Text] [Related]
2. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. Moul JW; Connelly RR; Perahia B; McLeod DG J Urol; 1998 Mar; 159(3):935-40. PubMed ID: 9474187 [TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase. Dattoli M; Wallner K; True L; Cash J; Sorace R Cancer; 2003 Feb; 97(4):979-83. PubMed ID: 12569596 [TBL] [Abstract][Full Text] [Related]
4. [Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay]. Akino H; Tsuka H; Okada K; Tsuchiya Y; Matsubara M; Arimura K Hinyokika Kiyo; 1995 Jun; 41(6):439-45. PubMed ID: 7544063 [TBL] [Abstract][Full Text] [Related]
5. Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies. Gunia S; Koch S; May M; Dietel M; Erbersdobler A Virchows Arch; 2009 May; 454(5):573-9. PubMed ID: 19301031 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia. Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815 [TBL] [Abstract][Full Text] [Related]
7. [Role of gamma-seminoprotein (gamma-SM) and prostatic acid phosphatase (PAP) as tumor markers of prostatic cancer]. Watanabe M; Kitamura Y; Komatsubara S; Sakata Y Hinyokika Kiyo; 1988 Dec; 34(12):2135-41. PubMed ID: 2467542 [TBL] [Abstract][Full Text] [Related]
8. Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy. Fang LC; Dattoli M; Taira A; True L; Sorace R; Wallner K Urology; 2008 Jan; 71(1):146-50. PubMed ID: 18242384 [TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer. Saito T; Hara N; Kitamura Y; Komatsubara S Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541 [TBL] [Abstract][Full Text] [Related]
10. [Clinical evaluation of gamma-seminoprotein as a serum marker of prostate carcinoma]. Sugimura Y; Sakurai M; Hioki T; Hayashi N; Yamakawa K; Tajima K; Tochigi H; Kawamura J Hinyokika Kiyo; 1988 Dec; 34(12):2129-34. PubMed ID: 2467541 [TBL] [Abstract][Full Text] [Related]
11. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate]. Morote Robles J; de Torres Mateos JA Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148 [TBL] [Abstract][Full Text] [Related]
13. [Experience with prostate-specific antigen in patients with prostatic cancer]. Romics I; Bach D Orv Hetil; 1989 Dec; 130(52):2797-800. PubMed ID: 2481833 [TBL] [Abstract][Full Text] [Related]
14. [Measurement of serum prostatic acid phosphatase (PAP) by Delfia PAP Kit using europium and clinical evaluation in patients with prostate cancer]. Akimoto S; Ohki T; Ichikawa T; Akakura K; Shimazaki J Hinyokika Kiyo; 1994 Nov; 40(11):987-93. PubMed ID: 7530404 [TBL] [Abstract][Full Text] [Related]
15. Changes in tissue prostatic acidic phosphatase during endocrine treatment of patients with prostatic carcinoma. Grande M; Carlström K; Lundh-Rozell B; Stege R; Pousette A Scand J Urol Nephrol; 2005; 39(5):393-8. PubMed ID: 16257841 [TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609 [TBL] [Abstract][Full Text] [Related]
17. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer. Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827 [TBL] [Abstract][Full Text] [Related]
18. [Prognosis of prostate cancer with elevated prostatic acid phosphatase]. Saito T; Kitamura Y; Komatsubara S Hinyokika Kiyo; 2006 Mar; 52(3):177-80. PubMed ID: 16617869 [TBL] [Abstract][Full Text] [Related]
19. [Clinical studies on tumor markers for monitoring prostate cancer patients; the evaluation of prostate-specific antigen and comparison with prostatic acid phosphatase and gamma-seminoprotein]. Shinoda I Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2627-39. PubMed ID: 1703555 [TBL] [Abstract][Full Text] [Related]
20. [Acid phosphatase (ACP)]. Igawa M; Kishi H; Ishibe T Nihon Rinsho; 1995 May; 53(5):1203-8. PubMed ID: 7602779 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]